CC BY-NC-ND 4.0 · Neurology International Open 2018; 2(02): E84-E92
DOI: 10.1055/s-0043-124983
Eigentümer und Copyright ©Georg Thieme Verlag KG 2018

Treatment Standards and Individualized Therapy of Myasthenia Gravis

Peter Paul Urban
1   Neurologische Klinik, Asklepios Klinik Barmbek, Hamburg
Christian Jacobi
2   Neurologische Klinik, Krankenhaus Nordwest GmbH, Frankfurt am Main
Sebastian Jander
3   Klinik für Neurologie, Universitätsklinikum Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
03 April 2018 (online)


A wide range of established treatment options is currently available for myasthenia gravis. These include cholinesterase inhibitors for symptomatic treatment and a broad spectrum of immunosuppressive, immunomodulating or cell-depleting options to modify the underlying immunological process. Appropriate use allows the great majority of patients to lead a normal life. Specialized centers integrating outpatient and in-hospital resources as well as interdisciplinary competences offer important advantages for optimum individualized therapy.